News

AbbVie Inc. stock underperforms Tuesday when compared to competitors
This was the stock's third consecutive day of losses.
Clinical Trials Arena7h
AbbVie’s Phase III trial of atogepant for migraine meets primary goal
AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...
AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for beginners now. In mid-May, AbbVie and ADARx Pharmaceuticals announced a collaboration and license option agreement. The partnership aims to ...
AbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial
AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.
AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C
AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval ...
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes
AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...
Crain's Chicago Business2d
RFK Jr. plans crackdown on pharma ads in threat to AbbVie's $2 billion marketing strategy
Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He’s long wanted to ...
Pharmaceutical Technology on MSN6d
FDA approves label expansion of AbbVie hepatitis C therapy
The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection
The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc’s (NYSE:ABBV) Mavyret ...
Medindia4d
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic ...